Where previous research showed that PSMA therapy for prostate cancer can prolong the lives of patients who have exhausted all ...
Investigators developed and validated new PSMA-PET-based nomograms for prognostication across prostate cancer stages to help ...
A randomized study in 58 men with limited metastatic prostate cancer found that PSMA therapy postponed the need for hormone ...
The study published by Bastiaan M Privé and colleagues in The Lancet Oncology represents, to our knowledge, the first randomised phase 2 trial evaluating lutetium-177–PSMA-617 (177Lu-PSMA-617) in ...
New FDA approvals and emerging trial data drive two pivotal 2026 NCCN guideline updates: lutetium-177 PSMA-617 for ...
Clarity Pharmaceuticals (ASX: CU6) (Clarity or Company), a clinical-stage radiopharmaceutical company with a mission to ...
The 2026 PSMA & Beyond conference featured a targeting the cell surface session and presentation by Dr. Tanya Dorff discussing antibody drug conjugates and BiTEs and their role in prostate cancer. Dr.
The 2026 PSMA & Beyond conference featured a clinical development session and presentation by Dr. William Maguire discussing regulatory considerations related to PSMA PET imaging in clinical trials.
Tagawa, MD, identified 3 primary clinical scenarios where PSMA PET scans have become the established standard for prostate cancer care. The first application is initial s ...
MedPage Today on MSN
PSMA-PET cuts need for biopsy in suspected prostate cancer
But does it cost too much?
A new radioactive diagnostic agent for use in prostate cancer has been approved by the US Food and Drug Administration (FDA). The product, Gallium 68 PSMA-11 (Ga 68 PSMA-11), has been approved for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results